A multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma
T.E. Merchant(St. Jude Children's Research Hospital), Amar Gajjar(St. Jude Children's Research Hospital), David L. Ashley(Georgia State University), Matthew J. Krasin(St. Jude Children's Research Hospital), V Ahern(Sydney Children's Hospital), M Sexton(Royal Children's Hospital), Murali Chintagumpala(Baylor College of Medicine), S.Y. Woo(Baylor College of Medicine), Stewart J. Kellie(Sydney Children's Hospital), L. Kun(Radiation Oncology Associates), Dana Jones-Wallace(St. Jude Children's Research Hospital)
International Journal of Radiation Oncology*Biology*Physics
September 12, 2003
Cited by 17
Related Papers
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
|Journal of Clinical Oncology|2010|657
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650